Catalio Capital Management, a US-based healthcare investment firm focused on university spinouts, closed the Nexus Fund IV yesterday, raising more than $400 million.
The capital is distributed across the Nexus Fund IV and co-investment vehicles, though Catalio did not specify individual sums.
The firm also did not identify any limited partners, noting only that they include both new and existing backers such as endowments, foundations, institutional investors, and registered investment advisers.
“We continue to see many compelling investment opportunities in this current market, including deals with prospects for near-term liquidity and deals with prospects for long-term growth.
“We are proud to invest in breakthrough biomedical technology companies developing drugs, devices, diagnostics, and tools that have potential for broad clinical impact and can enhance the lives of millions of patients around the world while delivering meaningful returns for our investors.”
Diamantis Xylas, Partner & Head of Research at Catalio
Catalio Capital Management was founded in 2020 and now manages $2 billion. The firm relies on a network of 45 venture partners, who provide access to a pipeline of deals.
Many of these venture partners are accomplished researchers and academic founders, such as George Church, the Robert Winthrop professor of genetics at Harvard Medical School, who has founded more than 20 spinouts to date.
To date, Catalio has backed more than 80 companies, including 16 investments already made through the Nexus Fund IV.
The firm’s fourth fund has also helped launch two new spinouts focused on immunology and inflammation: Rhapsogen, co-founded by venture partner Jeffrey Ravetch at Rockefeller University, and TBD Pharma, co-founded by venture partner Bert Vogelstein at Johns Hopkins University.